New Aromatic Bisabolane Derivatives with Lipid-Reducing Activity from the Marine Sponge Myrmekioderma sp.

• Published in: Marine Drugs
• Main Authors: Costa, Margarida, Coello, Laura, Urbatzka, Ralph, Pérez, Marta, Thorsteinsdóttir, Margrét
• Other Authors: Lyfjafræðideild (HÍ), Faculty of Pharmaceutical Sciences (UI), Heilbrigðisvísindasvið (HÍ), School of Health Sciences (UI), Háskóli Íslands, University of Iceland
• Format: Article in Journal/Newspaper
• Language: English
• Published: MDPI AG 2019
• Subjects: Bioactivity; Bisabolane-related compounds; Marine sponges; Natural compounds; Obesity; Whole small animal models; Náttúruefni (lyfjafræði); Svampdýr; Offita; Lyfjaefnafræði; Iceland
• Online Access: https://hdl.handle.net/20.500.11815/2048; https://doi.org/10.3390/md17060375

Publisher's version (útgefin grein) The previously reported 1-(2,4-dihydroxy-5-methylphenyl)ethan-1-one (1), (1’Z)-2-(1’,5’-dimethylhexa-1’,4’-dieny1)-5-methylbenzene-1,4-diol (2), and 1,8-epoxy-1(6),2,4,7,10-bisaborapentaen-4-ol (5) together with four new structures of aromatic bisabolane-related compounds (3, 4, 6, 7) were isolated from the marine sponge Myrmekioderma sp. Compounds 1, 2, and 5 were identified based on spectral data available in the literature. The structures of the four new compounds were experimentally established by 1D and 2D-NMR and (−)-HRESIMS spectral analysis. Cytotoxic and lipid-reducing activities of the isolated compounds were evaluated. None of the isolated compounds were active against the tested cancer cell lines; however, lipid-reducing activity was found for compounds 2–5 and 7 in the zebrafish Nile red fat metabolism assay. This class of compounds should be further explored for their suitability as possible agents for the treatment of lipid metabolic disorders and obesity. View Full-Text Funding: The research leading to these results received funding from the Marie Curie Actions of the European Union’s Seventh Framework Programme FP7/2007-2013/ under REA grant agreement No. 607786, BluePharmTrain, and by the European ERA-NET Marine Biotechnology project CYANOBESITY (ERA-MBT/0001/2015), financed by national funds through FCT (Foundation for Science and Technology, Portugal), RANNIS (Icelandic Center of Research, Iceland), and FCT strategic fund UID/Multi/04423/2019. Ralph Urbatzka was supported by FCT grant SFRH/BPD/112287/2015. Peer Reviewed